Posted by Michael Wonder on 28 Mar 2026
Bavarian Nordic submits data to EMA to extend mpox and smallpox vaccine approval to children aged 2-11 years
27 March 2026 - Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults.
Bavarian Nordic has submitted clinical data to the EMA to support the extension of the MVA-BN mpox and smallpox vaccine indication to include children aged 2 to 11 years.
